Physician profile
Daulath Singh
NPI 1568882876
$1,672.75
in general payments reported to CMS, 2019-2025
17 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $194 · 2024: $75.98 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $219 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $218.57 |
| Education | $131.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $265.04 | 2019-2020 | |
| Astellas Pharma US INC | $261.89 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $190.11 | 2019-2020 | |
| Seagen INC. | $174.99 | 2019 | |
| Celgene Corporation | $140.66 | 2019-2025 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $124.16 | 2019 | |
| Alexion Pharmaceuticals, INC. | $99.00 | 2019 | |
| Amgen INC. | $83.31 | 2019 | |
| Sanofi-Aventis U.S. LLC | $74.99 | 2025 | |
| Lilly USA, LLC | $56.69 | 2024 | |
| Pfizer INC. | $44.68 | 2025 | |
| Tempus Ai, INC | $41.90 | 2025 | Xt Cdx |
| Genzyme Corporation | $37.73 | 2024-2025 | |
| Pharmaessentia USA Corporation | $23.67 | 2025 | Besremi |
| Eisai INC. | $21.58 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $16.90 | 2025 | Enhertu |
| Genentech USA, INC. | $15.45 | 2025 | Itovebi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daulath Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.